Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.
All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.
Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to three new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) totaling 8,400 shares of common stock.
The RSUs will vest in three equal installments on April 1 of 2026, 2027, and 2028, contingent upon continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) has announced the dosing of the first patient in MAGNITUDE-2, a global Phase 3 trial of nexiguran ziclumeran (nex-z) for treating hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). This gene editing-based treatment aims to provide a one-time solution for this progressive, debilitating disease.
The trial builds on promising Phase 1 data that demonstrated nex-z's ability to achieve rapid, deep, and durable reduction in serum TTR levels with a single dose. The company plans to present extended Phase 1 data for both polyneuropathy and cardiomyopathy applications later this year, with a target to submit a biologics licensing application (BLA) for ATTRv-PN by 2028.
Intellia Therapeutics (NASDAQ:NTLA) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for nexiguran ziclumeran (nex-z) in treating transthyretin (ATTR) amyloidosis with cardiomyopathy. The therapy, also known as NTLA-2001, has demonstrated significant promise with rapid, durable and consistent reductions in serum TTR after a single dose, positively impacting disease progression markers.
The RMAT designation, established under the 21st Century Cures Act, will help expedite development and review processes. Benefits include early FDA interactions, discussions on surrogate endpoints for potential accelerated approval, and possible priority review of the biologics license application (BLA). Nex-z has also secured RMAT designations for polyneuropathy and Orphan Drug Designation from both U.S. FDA and European Commission.
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company, has granted inducement awards to eleven new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) for 32,600 shares of common stock.
The RSUs will vest in three equal installments on March 1 of 2026, 2027, and 2028, contingent upon continued employment. These equity awards were granted outside of Intellia's stockholder-approved plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these awards as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company has initiated dosing in the global Phase 3 HAELO study for NTLA-2002 in hereditary angioedema (HAE), with enrollment completion expected in H2 2025 and BLA submission planned for H2 2026.
The Phase 3 MAGNITUDE trial for nexiguran ziclumeran (nex-z) in ATTR amyloidosis is advancing ahead of schedule, targeting over 550 patients by year-end. The company maintains a strong financial position with $861.7 million in cash and equivalents as of December 31, 2024, expected to fund operations into H1 2027.
Q4 2024 financial results show collaboration revenue of $12.9 million, R&D expenses of $116.9 million, and G&A expenses of $32.4 million. The company reported a net loss of $128.9 million. In January 2025, Intellia announced a strategic restructuring, reducing workforce by 27% to focus on late-stage programs.
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has announced it will host a conference call on February 27, 2025, at 8 a.m. ET to discuss its fourth quarter and full-year 2024 financial results and operational highlights.
U.S. participants can dial 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will be available, and a replay will be accessible through the company's website starting at 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA) has announced the award of inducement grants to three new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units (RSUs) for 21,863 shares of common stock, which will vest in three equal installments on February 1 of 2026, 2027, and 2028. The vesting is contingent upon continued service with Intellia.
The awards were granted outside of Intellia's stockholder-approved equity incentive plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these grants as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) has announced the dosing of the first patient in its global Phase 3 HAELO study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema (HAE). The company expects to complete enrollment in the second half of 2025 and submit a biologics license application (BLA) in 2026, aiming for a U.S. launch in 2027.
NTLA-2002 is being developed as a single-dose treatment for this potentially life-threatening disease. The company plans to present longer-term data from the ongoing Phase 1/2 study later this year to demonstrate the treatment's durability of effect.
Intellia Therapeutics (NASDAQ:NTLA) announced strategic reorganization and 2025 milestones, focusing on two priority programs: NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for ATTR amyloidosis. The company plans to complete enrollment for the Phase 3 HAELO study in H2 2025 and aims to submit a Biologics License Application in H2 2026.
The reorganization includes discontinuing NTLA-3001 development and implementing a 27% workforce reduction in 2025, resulting in approximately $8 million in charges. With approximately $862 million in cash and investments at Q4 2024, combined with cost savings, the company expects to maintain operations into H1 2027.
Key 2025 objectives include enrolling over 550 patients in the MAGNITUDE study for nex-z, completing commercial leadership team buildout, and advancing medical education initiatives. The company also announced leadership changes, with CSO Laura Sepp-Lorenzino retiring and Birgit Schultes promoted to Executive VP and CSO.
Intellia Therapeutics (NASDAQ:NTLA) has granted inducement awards to three new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units (RSUs) for 23,155 shares of common stock, which will vest in three equal installments on January 1 of 2026, 2027, and 2028. The vesting is contingent upon continued employment with Intellia.
These awards were granted outside of Intellia's stockholder-approved equity incentive plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these grants as material inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4).
